An observational study in Low Back Pain, sponsored by International Institute of Behavioral Medicines. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-10.
Sponsored by International Institute of Behavioral Medicines · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Low Back Pain with a site in Italy — 12 open to participants now, 13 under way, 1 of them phase 3. Low Back Pain · Italy.
Among the 56 studies in Low Back Pain with a site in Italy, this one is the 9th largest by planned enrollment of the 15 observational ones that give a count, is one of 7 that started in 2023, is one of 16 observational ones, reaches primary completion later than 1 of the 12 other live ones, and was the 42nd registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →12 of the 56 studies in Low Back Pain with a site in Italy are open now. Recruiting first, the newest first:
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18–90
Manusapiens · Sites in Italy
Ages 20–40 · Women only · Healthy volunteers
Fondazione Don Carlo Gnocchi Onlus · Sites in Italy
Ages 18+
International Institute of Behavioral Medicines · Sites in Italy
Ages 11–30
Campus Bio-Medico University · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 5 · Phase 4 7
First in 2005; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 100 across 484 observational studies indexed under Low Back Pain.
Median enrollment 67 across the 40 interventional studies, 104 across the 15 observational. Of the 34 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 56 have an industry lead sponsor. The 10 most frequent:
International Institute of Behavioral Medicines is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
International Institute of Behavioral Medicines has 4 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
2 of the studies in Low Back Pain with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07568353G. d'Annunzio UniversityBrain Connectivity and Perceptive Surfaces in Chronic Low Back Pain (SUPER-RMNf) | 2027-05-31 |
| NCT07647757Federico II UniversityNeurolyser XR for the Treatment of Sacroiliitis | 2027-07 |
Add all 2 to your calendar (.ics) → With an account.
Among the 56 studies in Low Back Pain with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of this study is to describe the development of the Work In Progress questionnaire, a tool designed to evaluate commitment in persons, and its psychometric validation process in the context of low back pain.
The study design is cross-sectional.
The following methodology will be applied as for the development of the Work In Progress questionnaire (WIP), a tool designed to evaluate commitment in persons, and its psychometric validation:
People with non-specific low back pain. For full description od the condition, please see the definition provided within the references list (Chiarotto A et al).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
None (this is a non-interventional study)
WIP questionnaire
Work In Progress questionnaire; score varying from 0 to 30, with higher scores indicating greater commitment
Time frame: At the moment of the questionnaire administration
WIP questionnaire
Work In Progress questionnaire; score varying from 0 to 30, with higher scores indicating greater commitment
Time frame: After 7-10 days later the first assessment (please, see above) as concerns test-retest assessment reliability.
PCS
Pain Catastrophizing Scale; score varying from 0 to 52, with higher scores indicating greater catastrophizing
Time frame: At the moment of the questionnaire administration
ODI
Oswestry Disability Index; score varying from 0 to 50, with higher scores indicating greater disability
Time frame: At the moment of the questionnaire administration
pain NRS
Numerical pain Rating Scale; score varying from 0 to 10, with higher scores indicating greater pain intensity
Time frame: At the moment of the questionnaire administration
Plan to share: Undecided
Ran from Jul 2023 to primary completion in Jul 2023, 0 months.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
International Institute of Behavioral Medicines